west virginia glp-1 intestinal paralysis class action Weight Loss Drugs and Gastrointestinal Injuries: Patient Rights Centrally administered GLP-1 analogue improves

Patients who might be considered for GLP-1 therapy (within licensed indications) and who may experience secondary benefits for binge eating behaviours include: Individuals with binge eating disorder and type 2 diabetes , where GLP-1 agonists address the primary diabetes indication whilst potentially helping with eating patterns Those with BED and obesity who meet NHS eligibility criteria for weight management medications (as defined by NICE TA875 for semaglutide or TA664 for liraglutide, which are narrower than the marketing authorisation) Patients who have not responded adequately to psychological interventions such as cognitive behavioural therapy (CBT) and who have concurrent metabolic conditions Those experiencing significant food cravings and loss-of-control eating as part of their weight management challenges However, important cautions and considerations apply

Relief from related conditions like sleep apnea, fatty liver, and certain kidney disorders

Restoring fxr expression as a novel treatment strategy in liver cancer and other liver disorders

First, confirm baseline kidney function through serum creatinine and estimated glomerular filtration rate (eGFR) before starting either creatine or GLP-1 therapy

Clinical trials, including the LEAN trial, demonstrated significant histological remission of NASH following liraglutide treatment [246]